Integra LifeSciences Holdings Corporation Q2 FY2025 earnings call

Management Statement and Operational Highlights

• Compliance Master Plan: Completed assessments at all internal manufacturing sites ahead of Q3 timeline with no related shipholds since last earnings call. Remediation planning and execution underway with a risk-based road map prioritizing FDA regulations.
• Operational Excellence: Implemented a new supply chain control tower. Progress at Braintree facility for SurgiMend and PriMatrix relaunch in H1 2026, with quality management system on schedule and staffing model transitioned.
• Financial Results: Second quarter global revenue $415.6 million, exceeding guidance. Adjusted EPS $0.45. Goodwill impairment charge of $511 million due to macroeconomic uncertainties. Gross margin 60.7%, down 450 basis points due to shipholds remediation.
• Guidance Update: Q3 revenue guidance $410M-$420M, adjusted EPS $0.40-$0.45. Full-year revenue updated to $1.655B-$1.68B, adjusted EPS $2.19-$2.29, reflecting increased visibility on shipholds and market dynamics.

Segment Performance

• Codman Specialty Surgical (CSS): Reported second quarter revenue of $304 million, with 0.7% reported growth and -0.3% organic growth. Global neurosurgery revenues increased 0.3% organically, driven by CUSA platform, Aurora Surgiscope, etc., but offset by shipholds. ENT business had $30 million revenue from Acclarent integration, but growth below expectations due to reimbursement and timing issues.
• Tissue Technology: Second quarter revenue of $111.6 million, down approximately 4% on both reported and organic basis. Strong growth in Integra Skin, DuraSorb, MicroMatrix, Cytal, but offset by MediHoney shipholds and private label sales decline.

Guidance

• Q3: Expected revenue $410 million to $420 million (7.7%-10.3% reported growth, 7.3%-9.9% organic growth), adjusted EPS $0.40 to $0.45. Driven by strong global demand, seasonal improvement, and improved production yields for Integra Skin.
• Full Year: Revenue guidance updated to $1.655 billion to $1.68 billion, adjusted EPS $2.19 to $2.29. Reflects refined shiphold impact, market demand dynamics, and supply recovery progress.

Risks

• Macroeconomic uncertainties including tariffs and supply recovery risks impacting goodwill and margin.
• Shiphold impacts on revenue and gross margin due to remediation costs.
• Reimbursement changes affecting wound care products, potentially impacting market demand.

Question and Answer

• **Q: Thoughts on CMS' proposed 2026 reimbursement changes and impact on Integra?

A: Majority of business in acute care, long-term opportunity with evidence-backed products, but immediate impact limited.**

• **Q: Shipholds and 4Q impact?

A: Remediation ongoing, Q4 expected revenue lift from supply recovery and seasonal factors, with no new Compliance Master Plan related shipholds anticipated.**

• **Q: Customer winback and investment?

A: Confident in regaining business, but work needed for products like PriMatrix and SurgiMend, with a strong market for wound reconstruction products.**

• **Q: Revenue growth organic vs reported?

A: Lower organic midpoint due to shipholds, market demand decline, and slower market recapture, but better supply visibility reduces shiphold impact.**

• **Q: PriMatrix/SurgiMend revenue pre-off market?

A: ~$64 million annual in 2022, substitution limited, but confident in regaining share.**

• **Q: Tariffs impact?

A: Anticipated $13 million headwind in Q4, future impact uncertain as tariff landscape evolves.**